Perfusion Parameters in Dynamic Contrast-enhanced MRI and Apparent Diffusion Coefficient Value in Diffusion-weighted MRI:

Lee, Hyun Sil; Kim, Sung Hun; Kang, Bong Joo; Baek, Ji Eun; Song, Byung Joo

doi:10.1016/j.acra.2015.12.011

Cited by 34 publications

(25 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a statistically significant direct correlation of ADC mean with HER2-positive tumours ( P =0.009), which is in agreement with several previous papers (Martincich et al , 2012; Choi et al , 2012a; Richard et al , 2013; Park et al , 2015; Lee et al , 2016). In our population, we found a direct correlation between ADC mean and Ki-67 ⩽14% on biopsy ( P =0.025) and excision plus biopsy ( P =0.011).…”

Section: Discussionsupporting

confidence: 92%

“…Several prior studies have attempted to correlate different MR and PET biomarkers with breast cancer phenotypes including a high median ADC with HER-2 enriched tumours (Martincich et al , 2012), differences in ADC between multiple phenotypes (Richard et al , 2013; Lee et al , 2016), a low SUV max for luminal A tumours (Miyake et al , 2014), and increased SUV max with triple-negative breast cancers (Groheux et al , 2011; Yoon et al , 2014). While we agree that evaluating for the phenotype of a malignancy is important, rather than comparing the phenotypes by single parameters, we propose evaluating for phenotypes based on a multivariate algorithm.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype

et al. 2017

View full text Add to dashboard Cite

Background:Differences in genetics and receptor expression (phenotypes) of invasive ductal breast cancer (IDC) impact on prognosis and treatment response. Immunohistochemistry (IHC), the most used technique for IDC phenotyping, has some limitations including its invasiveness. We explored the possibility of contrast-enhanced positron emission tomography magnetic resonance (CE-FDG PET/MR) to discriminate IDC phenotypes.Methods:21 IDC patients with IHC assessment of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and antigen Ki-67 (Ki67) underwent CE-FDG PET/MR. Magnetic resonance-perfusion biomarkers, apparent diffusion coefficient (ADC), and standard uptake value (SUV) were compared with IHC markers and phenotypes, using a Student's t-test and one-way ANOVA.Results:ER/PR− tumours demonstrated higher Kepmean and SUVmax than ER or PR+ tumours. HER2− tumours displayed higher ADCmean, Kepmean, and SUVmax than HER2+tumours. Only ADCmean discriminated Ki67⩽14% tumours (lower ADCmean) from Ki67>14% tumours. PET/MR biomarkers correlated with IHC phenotype in 13 out of 21 patients (62% P=0.001).Conclusions:Positron emission tomography magnetic resonance might non-invasively help discriminate IDC phenotypes, helping to optimise individual therapy options.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In our study, we further reported the correlation between multiparametric DWI parameters and prognostic factors. No correlation between diffusion‐related parameters (ADC, D s , DDC, and MD) and tumor size was found, in accordance with previously reported literature data . However, tumors with diameters larger than or equal to 2 cm represented lower α values compared with smaller tumors.…”

Section: Discussionsupporting

confidence: 89%

“…Several studies have investigated the relationship of ADC with numerous pathologic prognostic factors in breast cancer such as tumor size, lymph node metastasis, histologic grade, and tumoral expressions of ER, PR, HER2, and Ki‐67 . In our study, we further reported the correlation between multiparametric DWI parameters and prognostic factors.…”

Section: Discussionmentioning

confidence: 64%

Multiparametric diffusion‐weighted imaging in breast lesions: Association with pathologic diagnosis and prognostic factors

Suo

Fang

Cao

et al. 2017

Magnetic Resonance Imaging

119

View full text Add to dashboard Cite

show abstract

“…However, to date results on ADC as a QIB to predict receptor status are divergent. We believe that this might be due to different measurement approaches, ie, measurements of the entire tumor vs. subjectively chosen areas, which have been utilized across studies . We hypothesized that ADC as a QIB can predict IHC receptor status, proliferation rate, and molecular tumor subtypes of breast cancer.…”

mentioning

confidence: 99%

Diffusion‐weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer

Horvat

Bernard‐Davila

Helbich

et al. 2019

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Background Diffusion‐weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping is one of the most useful additional MRI parameters to improve diagnostic accuracy and is now often used in a multiparameric imaging setting for breast tumor detection and characterization. Purpose To evaluate whether different ADC metrics can also be used for prediction of receptor status, proliferation rate, and molecular subtype in invasive breast cancer. Study Type Retrospective. Subjects In all, 107 patients with invasive breast cancer met the inclusion criteria (mean age 57 years, range 32–87) and underwent multiparametric breast MRI. Field Strength/Sequence 3 T, readout‐segmented echo planar imaging (rsEPI) with IR fat suppression, dynamic contrast‐enhanced (DCE) T1‐weighted imaging, T2‐weighted turbo‐spin echo (TSE) with fatsat. Assessment Two readers independently drew a region of interest on ADC maps on the whole tumor (WTu), and on its darkest part (DpTu). Minimum, mean, and maximum ADC values of both WTu and DpTu were compared for receptor status, proliferation rate, and molecular subtypes. Statistical Tests Wilcoxon rank sum, Mann–Whitney U‐tests for associations between radiologic features and histopathology; histogram and q‐q plots, Shapiro–Wilk's test to assess normality, concordance correlation coefficient for precision and accuracy; receiver operating characteristics curve analysis. Results Estrogen receptor (ER) and progesterone receptor (PR) status had significantly different ADC values for both readers. Maximum WTu (P = 0.0004 and 0.0005) and mean WTu (P = 0.0101 and 0.0136) were significantly lower for ER‐positive tumors, while PR‐positive tumors had significantly lower maximum WTu values (P = 0.0089 and 0.0047). Maximum WTu ADC was the only metric that was significantly different for molecular subtypes for both readers (P = 0.0100 and 0.0132) and enabled differentiation of luminal tumors from nonluminal (P = 0.0068 and 0.0069) with an area under the curve of 0.685 for both readers. Data Conclusion Maximum WTu ADC values may be used to differentiate luminal from other molecular subtypes of breast cancer. Level of Evidence: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;50:836–846.

show abstract

Perfusion Parameters in Dynamic Contrast-enhanced MRI and Apparent Diffusion Coefficient Value in Diffusion-weighted MRI:

Cited by 34 publications

References 21 publications

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype

Multiparametric diffusion‐weighted imaging in breast lesions: Association with pathologic diagnosis and prognostic factors

Diffusion‐weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer

Contact Info

Product

Resources

About